Replies to post #180327 on Biotech Values

[DewDiligence]

Re: ABT-MYL deal for branded generics in developed markets

As an addendum to my comments in #msg-104271033, I would submit that the RBC analyst report in your post is too kind to MYL. A more honest way to characterize this deal, IMO, is that ABT shrewdly exploited MYL’s desperation to do a tax inversion by unloading some of ABT’s least desirable assets at a good price.

I predict that ABT will rid itself of MYL shares within 6-9 months of the deal closing.